Acquisition of JAK2, PTPN11, and RAS mutations during disease progression in primary myelodysplastic syndrome

被引：37

作者：

Chen, C-Y ^{[1
]}

Lin, L-I

Tang, J-L

Tsay, W.

Chang, H-H

Yeh, Y-C

Huang, C-F

Chiou, R-J

Yao, M.

Ko, B-S

Chen, Y-C

Lin, K-H

Lin, D-T

Tien, H-F

机构：

[1] Natl Taiwan Univ, Coll Med, Dept Internal Med, Taipei 10018, Taiwan

[2] Natl Taiwan Univ, Coll Med, Dept Lab Med, Taipei 10018, Taiwan

[3] Natl Taiwan Univ, Coll Med, Dept Clin Sci & Med Biotechnol, Taipei 10018, Taiwan

[4] Natl Taiwan Univ, Coll Med, Dept Pediat, Taipei 10764, Taiwan

来源：

LEUKEMIA | 2006年 / 20卷 / 06期

关键词：

D O I：

10.1038/sj.leu.2404190

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1155 / 1158

页数：4

共 9 条

[1] Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [J].

Baxter, EJ ;

Scott, LM ;

Campbell, PJ ;

East, C ;

Fourouclas, N ;

Swanton, S ;

Vassiliou, GS ;

Bench, AJ ;

Boyd, EM ;

Curtin, N ;

Scott, MA ;

Erber, WN ;

Green, AR .

LANCET, 2005, 365 (9464) :1054-1061

[2]

HUGUES L, 2005, HAEMATOLOGICA, V90, P853

[3] Mutations in PTPN11 are uncommon in adult myelodysplastic syndromes and acute myeloid leukaemia [J].

Johan, MF ;

Bowen, DT ;

Frew, ME ;

Goodeve, AC ;

Wilson, GA ;

Peake, IR ;

Reilly, JT .

BRITISH JOURNAL OF HAEMATOLOGY, 2004, 124 (06) :843-844

[4] The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia [J].

Levine, RL ;

Loriaux, M ;

Huntly, BJP ;

Loh, ML ;

Beran, M ;

Stoffregen, E ;

Berger, R ;

Clark, JJ ;

Willis, SG ;

Nguyen, KT ;

Flores, NJ ;

Estey, E ;

Gattermann, N ;

Armstrong, S ;

Look, AT ;

Griffin, JD ;

Bernard, OA ;

Heinrich, MC ;

Gilliland, DG ;

Druker, B ;

Deininger, MWN .

BLOOD, 2005, 106 (10) :3377-3379

[5] RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias:: a 10-year follow-up [J].

Padua, RA ;

Guinn, BA ;

Al-Sabah, A ;

Smith, M ;

Taylor, C ;

Pettersson, T ;

Ridge, S ;

Carter, G ;

White, D ;

Oscier, D ;

Chevret, S ;

West, R .

LEUKEMIA, 1998, 12 (06) :887-892

[6] The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes [J].

Steensma, DP ;

Dewald, GW ;

Lasho, TL ;

Powell, HL ;

McClure, RF ;

Levine, RL ;

Gilliland, DG ;

Tefferi, A .

BLOOD, 2005, 106 (04) :1207-1209

[7] SHP-2 and myeloid malignancies [J].

Tartaglia, M ;

Niemeyer, CM ;

Shannon, KM ;

Loh, ML .

CURRENT OPINION IN HEMATOLOGY, 2004, 11 (01) :44-50

[8] Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia [J].

Tartaglia, M ;

Niemeyer, CM ;

Fragale, A ;

Song, XL ;

Buechner, J ;

Jung, A ;

Hählen, K ;

Hasle, H ;

Licht, JD ;

Gelb, BD .

NATURE GENETICS, 2003, 34 (02) :148-150

[9] Molecular characterization of specific interactions between SHP-2 phosphatase and JAK tyrosine kinases [J].

Yin, TG ;

Shen, R ;

Feng, GS ;

Yang, YC .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (02) :1032-1037

← 1 →